Aboleris Pharma is developing new immunomodulators for immune mediated diseases based on its know-how on T cell regulatory function. The vision is to rebalance the ratio of effector (Teff, pro-inflammatory) and regulatory (Treg, anti-inflammatory) functions. Teff /Treg imbalance with a predominance of Teff is at the heart of tissue destruction and organ functional impairment in auto-immune diseases, including inflammatory bowel diseases, rheumatoid arthritis, systemic lupus erythematosus. The company’s lead program is a monoclonal antibody “anti-CD45RC” (ABIS-45RC) to deplete Teff cells and preserve Treg cells.


Perseus Proteomics

Perseus Proteomics developed an antibody drug discovery platform based on phage display. It focuses on therapeutic antibody development targeting transferrin receptor (TfR) for various blood cancer diseases. The company licensed out 2 product candidates and possesses 1 internal product candidate (PPMX-T003) for development in Polycythemia Vera (excess prodution of red blood cells), a precursor to other hematological malignancies. in Japan. PPMX-T003 targets TfR that is expressed on the cell membrane and regulates cellular iron uptake in all cells, especially those manufaturing hemoglobin. The cellular iron uptake is essential for these cell survival and proliferation. The trial in polycythemia investigates the feasibility of reducing red blood cells to a normal level, avoiding the need for nedessary blood letting to avoid complications, such as uncontrolled hypertension and thrombotic episodes.


Acticor Biotech

Acticor Biotech is a clinical stage biotechnology company, spin-off of INSERM, dedicated to developing an innovative treatment in the therapy of acute thrombotic diseases, including ischemic stroke and pulmonary embolism. It has developed a product from a fragment of an antibody (Glenzocimab) targeting the platelet Glycoprotein VI to accelerate the thrombus dissolution rate in acute ischemic stroke treated with thrombolysis, without increasing the risk of bleeding. The product is developed as an add-on therapy to thrombolysis treatment in thrombo-embolic diseases. The two major ongoing clinical trials are the ACTIMIS project (a Phase IIa study, placebo controlled, to document safety in ischemic stroke and the ACTISAVE project (an international US – EU Phase II-III adaptive randomized placebo-controlled trial in ischemic stroke).